Mit dem neuen Format "gfh-genetalks-online" offeriert die GfH allen Mitgliedern und Interessierten eine Kommunikationsplattform, die einmal monatlich – voraussichtlich immer mittwochs – stattfinden soll. In 1 ½ stündigen Sessions präsentieren herausragende Experten unseres Faches ihre wissenschaftlichen Ergebnisse und Highlights, bei denen Sie die Möglichkeit erhalten, in die Diskussion einzusteigen und Fragen zu stellen. Die Teilnahme ist kostenlos. Die Zugangsdaten werden 1 Woche vor der Termin an dieser Stelle bekannt gegeben. Die Auswahl der SprecherInnen und Themen liegt in den Händen der GfH-Programmkommission. 


gfh-genetalk-online 4 ..... 21.7.2021 .....  18:00 - 10:30 Uhr

Prof. Dr. Hildegard Büning: Gene Therapy – Status and Future Direction

As indicated by the 10 market approvals in the Western World, gene therapy has reached the clinical reality. Instead of treating symptoms, gene therapy offers the chance to cure a genetic disease by providing a function gene copy, by counteracting the activity of a malfunctioning gene or – with the advent of genome editing – by repairing the underlying genetic mutation. The range of applications was greatly expanded and currently encompass monogenetic diseases, cancer, and infectious diseases. Despite this success, the full potential of gene therapy has not been fully unlocked so far. Current challenges as well as strategies followed to tackle these challenges will be discussed.

Login-Data: t.b.a. 

Stefan Mundlos

Prof. Dr. rer.nat. Hildegard Büning

Deputy Director of the Institute of Experimental Hematology, Hannover Medical School,
REBIRTH Center for Translational Regenerative Medicine, Hannover Medical School, Hannover, Germany 
Hildegard Büning is Professor of Infection Biology of the Gene Transfer and Deputy Director of the Institute of Experimental Hematology at Hannover Medical School (Hannover, Germany). 
She serves as current President of the European Society of Gene and Cell Therapy (www.ESGCT.eu) and Scientific Secretary of the German Society for Gene Therapy (www.dg-gt.de). 
She studied Biology in Münster and Munich and obtained her PhD (Dr. rer. nat.) at the Ludwig-Maximilians University Munich in 1997. Since then, she is active in the field of adeno-associated virus (AAV) vectors with a particular focus on AAV-host interactions and AAV vector development. Aiming to optimize efficacy, specificity, and safety of AAV vectors for gene therapy and regenerative medicine, her research team is developing strategies to modify tropism and immunogenicity of AAV vectors using both rational design and library-based approaches.


gfh-genetalk-online 3..... 23.6.2021 

Prof. Dr. Jay Shendure: New Frontiers in Genetics and Genomics

Jay Shendure works on developing and applying novel methods in genetics and genomics. His work has had a tremendous influence on the field of human genetics through the development of Exom sequencing in 2009 and performing the first non-invasive fatal genome sequencing from cell-free DNA in 2012. Since then, his lab has pioneered the development of several new single-cell technologies.
The Shendure lab has developed a multiplex, expression quantitative trait locus (eQTL)-inspired framework for mapping enhancer-gene pairs by introducing random combinations of CRISPR/Cas9- mediated perturbations to each of many cells, followed by single-cell RNA sequencing (RNA-seq). The framework, termed crisprQTL, has enabled us to vastly increase the number of functionally supported enhancer-gene pairings, as well as to assess the background distribution of genomic distances between enhancers and the genes that they regulate.

gfh-genetalk-online 2..... 26.5.2021 

Prof. Dr. Mark Rubin: Understanding Lineage Plasticity as a Mechanism for Therapy Resistance using Prostate Cancer as a Model

Mark A. Rubin, MD, Professor, Principal Investigator, and Director of the Department for BioMedical Research (DBMR), University of Bern, Switzerland. Prof. Mark Rubin is a recognized world-renown leader in prostate cancer genomics and pathology, and precision medicine. Dr. Rubin’s laboratory led a series of landmark studies defining distinct molecular features of prostate cancer, revealing pathways that are perturbed and drive different types of this cancer. Furthermore, Prof. Rubin has translated many of his genomic discoveries into clinical tests that are currently patented and standardly used in the diagnosis and treatment of prostate cancer. Prof. Rubin founded the Englander Institute for Precision Medicine and, more recently, the Bern Center for Precision Medicine (BCPM).

gfh-genetalk-online 1 ..... 21.4.2021

Prof. Dr. Stefan Mundlos: Unraveling the secrets of the non-coding genome

Mit einem Vortrag von Prof. Dr. Stefan Mundlos, Berlin, eröffneten wir am 21.4.2021 (18:00-19:30) unsere neue Vortragsreihe "gfh-genetalks-online". Insgesamt nahmen 215 TeilnehmerInnen teil. Die Rückmeldungen waren absolut positiv: "Ganz toller Talk, auch didaktisch richtig gut aufbereitet, und faszinierender Mechanismus! Ich schwärme heute noch davon." "Das war prima, herzlichen Dank für die Organisation, auch zeitlich ideal und sehr gut organisiert mit dem ZOOM-Zugang." "Vielen Dank! Sehr gute Idee – und exzellente Umsetzung! "